sirolimus + tacrolimus

This entry refers to the comparative evaluation or combination use of sirolimus and tacrolimus in a clinical trial context led by Wayne State University for kidney transplantation. Sirolimus (Rapamune) is an mTOR inhibitor that suppresses T-lymphocyte activation and proliferation by inhibiting the response to interleukin-2 (IL-2) and other T-cell growth factors. Tacrolimus (Prograf) is a calcineurin inhibitor that prevents the transcription of IL-2 and other cytokines, thereby inhibiting T-cell activation. The Wayne State University pilot study specifically investigated these agents in African-American renal allograft recipients with immediate graft function to determine the optimal steroid-free immunosuppressive regimen for this high-risk population, comparing the efficacy of sirolimus versus tacrolimus in maintaining graft function and preventing acute rejection.

Brand names

RapamunePrografAdvagrafEnvarsus XR

Other names

RapamycinFK-506FK506FK 506fujimycin